文献速递泌尿生殖介入PETCT

18F-胆碱PET/CT驱动的挽救性放疗在前列腺癌患者中的应用:中位随访5年的更新分析

18F-choline PET/CT driven salvage radiotherapy in prostate cancer patients: up-date analysis with 5-year median follow-up.
PubMed 文献 · Radiol Med · 2020-03-12

中位随访63.5个月,5年和7年无复发生存率分别为70%和60.7%,晚期毒性发生率低,作者认为该方案可行且初步有效。

要点

  • 生化复发时动态18F-胆碱PET/CT可定位局部复发灶,指导对生物学靶区行剂量提升至80 Gy。
  • 139例(93%)患者无中断完成挽救性放疗,急性≥2级胃肠道毒性13例(9%),≥2级泌尿生殖毒性2例(1.4%)。
  • 中位随访63.5个月,5年和7年无复发生存率分别为70%和60.7%。

核心结论

  • 中位随访5年的本研究证实,对生物学靶区行高剂量挽救性放疗是可行的,晚期毒性发生率低且初步疗效可观。

关键影像表现/征象

  • 动态18F-胆碱PET/CT在生化复发时识别局部复发部位,作为生物学靶区指导剂量提升。
  • 挽救性放疗开始时中位PSA值为0.47 ng/ml(范围0.2-17.5 ng/ml)。

诊断标准与关键数值

  • 挽救性放疗总剂量达80 Gy,照射18F-胆碱PET/CT阳性区域。
  • 5年和7年无复发生存率分别为70%和60.7%。
  • 急性胃肠道≥2级毒性13例(9%),急性泌尿生殖≥2级毒性2例(1.4%)。
  • 晚期胃肠道4级毒性1例(0.7%),晚期泌尿生殖3级毒性2例(1.4%)。

临床应用与阅片要点

  • 生化复发时动态18F-胆碱PET/CT可用于定位局部复发灶并指导对生物学靶区行剂量提升至80 Gy。
  • 139例(93%)患者无中断完成挽救性放疗,治疗可行性高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Salvage radiotherapy is generally considered as the standard treatment for biochemical relapse after surgery. Best results have been obtained with a PSA value < 0.5 ng/ml at relapse, while 60-66 Gy is deemed as standard total dose. Modern imaging, as dynamic-18F-choline PET/CT may identify site of recurrence, allowing dose escalation to a biological target volume.

METHODS: Hundred and fifty patients showed a local relapse at dynamic-18F-choline PET/CT at time of biochemical recurrence. High-dose salvage radiotherapy was delivered up to total dose of 80 Gy to 18F-choline PET/CT positive area. Toxicity and relapse-free survival were recorded.

RESULTS: Median PSA value at the beginning of salvage radiotherapy was 0.47 ng/ml (range 0.2-17.5 ng/ml). One-hundred and thirty nine patients (93%) completed salvage radiotherapy without interruptions. Acute gastrointestinal grade ≥ 2 toxicity was recorded in 13 patients (9%), acute genitourinary grade ≥ 2 toxicity in 2 patients (1.4%). One patient (0.7%) experienced late gastrointestinal grade 4 toxicity and 2 patients (1.4%) late acute genitourinary grade 3 toxicity. With a median follow-up of 63.5 months, 5 and 7-years relapse-free survival were 70% and 60.7%, respectively.

CONCLUSION: With a median follow-up of 5 years the present study confirms that high-dose salvage radiotherapy to a biological target volume is feasible, with low rate of late toxicity and promising activity.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. D'Angelillo RM, Fiore M, Trodella LE, et al. 18F-choline PET/CT driven salvage radiotherapy in prostate cancer patients: up-date analysis with 5-year median follow-up. Radiol Med. 2020. PMID: 32166718. doi:10.1007/s11547-020-01167-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。